Affle 3I Limited has completed the allotment of 74 lakh convertible warrants to its promoter, Affle Holdings Pte. Ltd. This move brings a capital infusion of ₹275.10 crore to the company. The warrants are convertible into equity shares within 18 months.

Affle 3I Ltd Completes ₹275 Crore Warrant Allotment to Promoter

Affle 3I Limited has successfully completed the allotment of 74 lakh convertible warrants to its promoter entity, Affle Holdings Pte. Ltd., infusing ₹275.10 crore into the company. This capital infusion represents 25% of the total issue price for these warrants.

Reader Takeaway: Strategic promoter funding strengthens liquidity, but potential equity dilution looms.

What just happened

Affle 3I Limited announced the completion of the allotment of 74 lakh convertible warrants to its promoter, Affle Holdings Pte. Ltd. The subscription amount received is ₹275.10 crore, which is 25% of the total issue price.

Why this matters

This preferential allotment signifies a strong commitment from the promoter and provides the company with significant capital. It will bolster the company's financial resources for its growth initiatives. However, the eventual conversion of these warrants into equity shares will lead to a dilution of existing shareholders' stakes.

The backstory

The Board of Directors approved the allotment on June 18, 2026. This follows a special resolution passed by shareholders on June 10, 2026, and in-principle approval from the stock exchanges on June 12, 2026.

What changes now

The 74 lakh warrants, priced at ₹1,487 per warrant (including a premium of ₹1,485), grant the holder the right to subscribe to one equity share of face value ₹2. The conversion into equity shares is dependent on the payment of the remaining 75% of the issue price within the 18-month tenure from the allotment date.

Risks to watch

Existing shareholders face the risk of equity dilution when the warrants are converted. If the promoter does not exercise the conversion option within the 18-month period, the subscription amount of ₹275.10 crore will be forfeited, which could impact the company's cash flow. Investors must monitor the company's performance and growth plans to assess the value accretion from this capital infusion.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Allotment Date: June 18, 2026
• Shareholder Approval: June 10, 2026
• Exchange Approval: June 12, 2026
• Warrant Tenure: 18 months from allotment
• Capital Infused: ₹275.10 crore
• Warrants Allotted: 74 lakh (7,400,000)
• Issue Price per Warrant: ₹1,487
• Face Value per Share: ₹2

What to track next

Investors should track the conversion of these warrants into equity shares and the company's utilization of the infused capital. The timeline for conversion and any future announcements regarding capital expenditure or business expansion will be crucial.